Efeito da dorzolamida em glaucoma crônico simples

Efeito da dorzolamida em glaucoma crônico simples

Autores:

C. E. L. Arieta,
J. F. Serpa,
W. A. Marchi Jr,
N. Kara José

ARTIGO ORIGINAL

Arquivos Brasileiros de Oftalmologia

versão impressa ISSN 0004-2749versão On-line ISSN 1678-2925

Arq. Bras. Oftalmol. vol.59 no.6 São Paulo dez. 1996

http://dx.doi.org/10.5935/0004-2749.19960014

SUMMARY

The effects of the use of 2% topic Dorzolamide, a carbonic anhydrase inhibitor, were observed in 22 eyes (11 patients), with emphasis on the IOP, corrected visual acuity and perimetry, and its side effects on the cornea, conjuntiva, anterior chamber, lens, fundus and clinical and laboratorial exams (blood count, sodium and potassium). There was a decrease of 26,8% in IOP after 30 days of treatment, with persistence of this effect during a period of one year. Six patients had an deteriotation of the perimetry, and in three of them it was inespecific. There was no significant variation on the mean visual acuity during treatment. Mild side effects were observed in a few patients, but they were not found in subsequent examination. There was no laboratorial changes in the patients studied.

REFERÊNCIAS

1 BRANDT, J. D. - Carbonic anhydrase inhibitors. CLAO J., 17(2): 136-138, 1991.
2 HIGGINBOTHAM, E. J. - Topical carbonic anhydrase inhibitors. Ophthalmic Clin. North. Am., 2(1): 113-130, 1989.
3 WILKERSON, M. et al. - Four week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch. Ophthalm., 111: 1343-1349, 1993.
4 LIPPA, E. A.; VON DENFFER, H. A.; HOFMANN, H. M.; BRUNNER-FERBES, F. L. - Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor. Arch. Ophthalm., 106: 1694-1696, 1988.
5 HIGGINBOTHAM, E. J. et al - MK-927, a topical carbonic anhydrase inhibitor: dose response and duration of action. Arch. Ophthalm., 108: 65-68, 1990.
6 STRAHLMAN, E.; TIPPING, R.; VOGEL, R. and the International Dorzolamide Study Group. A double masked, randomized 1-year study comparing Dorzolamide (Trusopt), timolol, and betaxolol. Arch. Ophthalm., 113: 1009-1016, 1995.
7 LIPPA, E. A.; CLINESCHMIDT, C. M.; TIPPING, R. W.; STROHMAIER, K. M. - and the Dorzolamide Dose-Response Study Group. Dorzolamide Hydrochloride: six-week, dose response, study of an active topical carbonic anhydrase inhibitor. Invest. Ophthalm. Visual Sci, 34: 913, 1993.
8 MAREN, T. H. - A comparision between topical and oral sulfonamides in treatment of elevated ocular pressure in man. Invest. Ophthalm. Visual Sci, 33(4): 1246, 1992.
9 BERSON, F. G.; EPSTEIN, D. I. - Separate and combined effects of timolol maleate and acetazolamide in open-angle glaucoma. Am. J. Ophthalm. 92: 788-791, 1981.
10 COHEN, R.; MANDIA Jr, C.; ALMEIDA, G. V. - Betaxolol a 0,25% suspensão iônica x betaxolol a 0,25%: estudo comparativo. Arq. Bras. Oftalm., 58(6): 417-420, 1995.
Política de Privacidade © Copyright, Todos os direitos reservados.